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Iron modulates cell survival in a Ras- and
MAPK-dependent manner in ovarian cells
KA Bauckman1, E Haller2, I Flores3 and M Nanjundan*,1,4
Ovarian cancer is a leading cause of cancer death in women in the United States. While the majority of ovarian cancers are
serous, some rarer subtypes (i.e. clear cell) are often associated with endometriosis, a benign gynecological disease. Iron is rich
in the cyst fluid of endometriosis-associated ovarian cancers and induces persistent oxidative stress. The role of iron, an
essential nutrient involved in multiple cellular functions, in normal ovarian cell survival and ovarian cancer remains unclear. Iron,
presented as ferric ammonium citrate (FAC), dramatically inhibits cell survival in ovarian cancer cell types associated with
Ras mutations, while it is without effect in immortalized normal ovarian surface epithelial (T80) and endometriotic epithelial cells
(lacking Ras mutations). Interestingly, FAC induced changes in cytoplasmic vacuolation concurrently with increases in LC3-II
levels (an autophagy marker); these changes occurred in an ATG5/ATG7-dependent, beclin-1/hVps34-independent, and
Ras-independent manner. Knockdown of autophagy mediators in HEY ovarian cancer cells reversed FAC-induced LC3-II levels,
but there was little effect on reversing the cell death response. Intriguingly, transmission electron microscopy of FAC-treated
T80 cells demonstrated abundant lysosomes (confirmed using Lysotracker) rich in iron particles, which occurred in a
Ras-independent manner. Although the mitogen-activated protein kinase (MAPK) inhibitor, U0126, reversed FAC-induced LC3-II/
autophagic punctae and lysosomes in a Ras-independent manner, it was remarkable that U0126 reversed cell death in malignant
ovarian cells associated with Ras mutations. Moreover, FAC increased heme oxygenase-1 expression in H-Ras-overexpressing
T80 cells, which was associated with increased cell death when overexpressed in T80 cells. Disruption of intracellular iron levels,
via chelation of intracellular iron (deferoxamine), was also detrimental to malignant ovarian cell survival; thus, homeostatic
intracellular iron levels are essential for cell survival. Collectively, our results implicate iron in modulating cell death in a
Ras- and MAPK-dependent manner in ovarian cancer cells.
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Ovarian carcinoma is the fifth most common cancer for
women in the United States and is usually diagnosed at an
advanced stage when the cancer has already spread.1
Several ovarian cancer subtypes exist that elicit differential
responses to chemotherapy. Clear cell ovarian carcinoma
(CCC, a rare subtype) is more resistant to chemotherapy
compared with serous epithelial ovarian cancers, the major
epithelial ovarian carcinoma (EOC).2 Endometriotic cysts,
considered a precursor to endometriosis-associated ovarian
cancers, contain a high level of heme,3,4 which can be broken
down via the action of heme oxygenase-1 (HO-1) to release
iron, biliverdin, and carbon monoxide; these products
increase oxidative stress that alters cell survival and
contribute to cancer development.3,4 Treating normal ovarian
surface epithelial cells with redox-active iron promotes
acquisition of a CCC signature.5 Iron can also induce cell
death in cell types associated with Ras mutations.6 Thus, iron
may elicit dual functional roles in cancer development.
Reactive oxygen species (ROS) can also be generated via
hypoxia, correlated with elevated LC3A (a marker of
autophagy) expression in CCC associated with hypoxic
regions and poor patient outcome.7 Autophagy is a self-
eating process where damaged and oxidized cellular material
are sequestered in autophagosomes and then degraded
within lysosomes.8 Autophagy elicits tumor suppressive
effects in normal cells, while under conditions of oxidative
stress, autophagy sustains survival of cancer cells. It is
presently unknown whether oxidative stress induced by iron
alters autophagy to modulate cell survival in normal and
malignant ovarian cells.
Herein, we present data implicating iron in inhibiting cell
survival in ovarian cancer cell types associated with Ras
mutations. Iron elevates LC3-II levels in multiple cell types in
an ATG5/ATG7-dependent and beclin-1/hVps34-indepen-
dent fashion. However, knockdown of autophagy mediators
resulted in only a modest reversal of cell death. Iron also
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induced an increase in lysosome numbers in a Ras-
independent manner. Inhibition of the mitogen-activated
protein kinase (MAPK) pathway in ovarian cancer cells
dramatically reversed iron-induced LC3-II levels and lyso-
some numbers. Strikingly, this inhibitor reversed the cell death
response in cell lines associated with Rasmutations. Iron also
induced cell death via upregulation of HO-1 in a nuclear factor
(erythoid-derived 2)-like 2 (NRF2)-independent but Ras-
dependent manner. Modulation of intracellular levels of iron
(via chelation with deferoxamine (DFO)) also disrupts cell
survival, implicating a need to critically monitor and maintain
appropriate levels of cellular iron for cell survival. Collectively,
we demonstrate that iron modulates cell death in ovarian
cancer cell types in a Ras- and MAPK-dependent manner.
Results
FAC modulates cell survival in ovarian cell types
associated with Ras mutations. To determine the effect
of long-term treatment with iron (presented as ferric
ammonium citrate, FAC) on normal and ovarian carcinoma
cell lines, we performed growth assays (Figure 1a and
summarized in Figure 1b). As normal cells, we used T80
cells, which are immortalized (LTAg/hTERT) normal ovarian
surface epithelial cells, from which the T80þH-Ras and
T80þK-Ras cells were derived via the overexpression of
Ras9 as well as human epithelial endometrial cells (HES), a
normal endometrial epithelial cell line, recently reported to
express markers of HeLa cells.10 Immortalized endometriotic
(IE) are SV40 LTAg immortalized normal endometriotic cells
developed from primary cells (Bello et al., unpublished work).
Screening for mutations in PI3K catalytic subunit (PIK3CA)
(exon 9 and 20) and K-Ras using IE genomic DNA failed to
identify any mutated sequences, implicating normal features
for this cell line. For epithelial ovarian cancer cell lines, we
assessed HEY (a serous epithelial ovarian cancer cell line)
and TOV21G cells (a clear cell epithelial ovarian cancer cell
line) containing Ras mutations as well as TOV112D cells (an
endometrioid epithelial ovarian cancer cell line), which has no
Ras mutations thus far identified.11,12 Surprisingly, we found
that 250mM FAC induced a marked growth inhibition in HEY
and TOV21G ovarian cancer lines in contrast to a modest or
no effect in the ‘normal’ cell types (T80, HES, and IE).
Although TOV112D displayed a reduction in cell growth with
FAC, it was less dramatic compared with HEY and TOV21G.
To determine whether Ras altered cellular responsiveness to
iron, T80 cells overexpressing H-Ras and K-Ras were
assessed.9 Ras-overexpressing T80 cells show a striking
reduction in cell growth with FAC in contrast to parental T80
cells (Figures 1a and b). These results implicate increased
iron-sensitivity in cancer cells associated with Ras mutations
or in normal cells overexpressing Ras.
To obtain further insight into the nature of FAC-mediated
growth reduction, we initially assessed whether FAC induced
senescence. Although FAC-treated cells lacked markers of
senescence (b-galactosidase staining) (results not shown),
cell cycle analysis demonstrated a significant 47% increase
in cells in G1 with a corresponding reduction of 3% of cells
in S phase following 72 h FAC treatment (Supplementary
Figure 1a). Similar increases in the percentage of G1 phase
cells were obtained in HEY and TOV21G (results not
presented). These results indicate that FAC induces accu-
mulation of cells in the G1 phase. To assess apoptosis (via
annexin V/PI staining (Figure 1c)), FAC-treated HEY and
T80þH-Ras cells displayed a significant increase in the
percentage of early and late apoptotic/necrotic cells. In
contrast, FAC did not induce an apoptotic response in
TOV21G, although marked changes in cellular morphology
were observed via light microscopy (Figure 1c). Intriguingly,
we observed that FAC induced a marked necrotic cell death
response in HEY cells (Figure 1c) as observed via light
microscopy/PI staining, and validated by measuring lactate
dehydrogenase (LDH) activity (Figure 1d).
To determine whether FAC could modulate changes in
cellular metabolic activity, we quantified ATP levels following
72 h FAC treatment in ‘normal’ and malignant ovarian cells.
A significant reduction in ATP levels was observed in HEY and
TOV21G cells; however, there was no difference between
T80 and T80þH-Ras cells, suggesting that FAC-mediated
changes in ATP occur via a Ras-independent mechanism
(Figure 1e). We further observed a dramatic effect on
the inhibition of migration in all assessed cell types,
(Supplementary Figure 1b) suggesting that FAC can mediate
other functional effects in ovarian cells.
FAC alters autophagy in a Ras-independent manner,
which contributes only a modest effect to the cell death
response. As we observed increased cytoplasmic vacuole
formation (a feature of autophagy) with 250mM FAC in T80
cells (Figure 2a), we next assessed whether FAC could alter
levels of LC3-II, a marker of autophagy. Transmission
electron microscopy (TEM) documented the presence of
double-membrane autophagosomes (Figure 2b). We also
noted a clear LC3-II increase in T80 cells with increasing
doses of FAC (5mM to 10mM, Figure 2c). Moreover, we
noted the activation of AKT and MAPK within 1 h of FAC
treatment, suggesting changes in LC3-II could be mediated
via the activation of these pathways (Figure 2d). We
identified optimal FAC doses for the ovarian cancer cell
lines used (HEY, TOV21G, and TOV112D) (Supplementary
Figures 2a–d). Increases in LC3-II levels were also observed
in ovarian cancer cell lines (HEY, TOV21G, and TOV112D),
(Figure 2e) suggesting that FAC could alter the autophagic
response in multiple gynecological cell types. Among the
cancer cell lines, HEY elicited the most robust LC3-II
response, while TOV112D was the least responsive. FAC
treatment of IE cells induced a similar LC3-II response
relative to T80 cells (Figure 2f). In all cell lines assessed, we
noted that FAC increased ferritin levels (FTH, Figures 2e
and f). FTH is known to bind free redox-active iron as a
cytoprotective pathway. Thus, we assessed the expression
level of genes involved in modulating cellular iron
content, including the transferrin receptor (CD71) and FTH,
which could mediate the observed differential cellular
response of FAC. However, we did not identify any
association between CD71, ferritin, and LC3-II under our
conditions (Supplementary Figure 3).
We noted the basal level of LC3-II was highest in HEY and
TOV21G, and moderate in TOV112D (Supplementary
Figure 4a). Autophagic inhibition (using 25 mM chloroquine
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(CQ), an agent used to inhibit autophagosome–lysosome
fusion) increased LC3-II levels and inhibited cell survival of
both the normal and cancer-derived ovarian cell types,
assessed via colony formation assays (Supplementary
Figure 4b). These results implicate basal autophagy in
mediating cell survival in multiple ovarian cell types. To
determine whether the increase of LC3-II with FACwas due to
autophagy induction or autophagosomal accumulation, cells
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Figure 1 Effect of FAC on ‘normal’ and malignant gynecological cell survival. (a) Growth assays were performed in IE, HES, T80, T80þH-Ras, T80þK-Ras, HEY,
TOV21G, and TOV112D cells from Day 1 to Day 5 in the absence or presence of 250mM FAC. Results are representative of three independent experiments. (b) Data
presented in (a) are presented in tabular format as the percentage changes in growth for all the cell lines assessed. In addition, a cell line description and Ras overexpression/
mutation status are summarized for each cell line used. (c) T80, T80þH-Ras, HEY, or TOV21G cells were treated with 250mM FAC for 72 h, at which time both the floating
and adherent cells were collected. Cells were stained with annexin V-FITC and propidium iodide (PI) followed by flow cytometric analysis. Light microscope images of these
cells are shown in the left panels; raw data plots of apoptosis assays are shown in the middle panels; the percentages of viable and dead cells are shown in the right panels.
Results are representative of two independent experiments. (d) HEY cells were treated with 250mM FAC for 72 h followed by LDH cytotoxicity assay measurements. Results
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were cotreated with CQ and FAC. CQ further increased the
levels of LC3-II with 250mM FAC (Figures 2g–i), suggesting
this dose of FAC mediates autophagic induction (increased
autophagic flux). In contrast, LC3-II did not further accumulate
following 5mM FAC in combination with CQ, suggestive of
autophagosomal accumulation (decreased autophagic flux).
p62 levels were variable in response to FAC in the different
cell types as well as in response to different doses of FAC
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captured at  40 magnification. (b) T80 cells treated for 18 h with 250mM FAC were subjected to TEM, which identified double-membrane autophagosomes (purple arrows).
(c) T80 cells were treated with increasing doses of FAC (5mM–10mM). Cell lysates were harvested and analyzed by western blotting for the proteins indicated. Results are
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lysates were harvested and analyzed by western blotting for the proteins indicated. Results are representative of two independent experiments. (f) IE cells were treated with increasing
doses of FAC (0.25–5mM) for 18 h. Cell lysates were harvested and analyzed by western blotting for the proteins indicated. Results are representative of two independent experiments.
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Cell lysates were harvested and western blotting performed for the proteins indicated. Results are representative of two independent experiments. (h) IE cells were treated with
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punctae was quantified by counting cells with420 punctae. (l) HEY cells were transfected with GFP–LC3. Following 18 h FAC treatment, western analyses were performed using the
indicated antibodies. Results are representative of two independent experiments. * refers to Po0.05
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(Supplementary Figures 2a–d). Although increased p62
levels can be considered a marker of reduced autophagic
flux, p62 has other functional roles.13,14 To validate the
induction of autophagy upon FAC treatment, we transfected
T80 cells with enhanced green fluorescent protein (EGFP)–
LC3 plasmid followed by 250 mM FAC treatment. The
transition from diffuse to punctate GFP expression induced
by FAC suggests LC3-II becomes associated with autopha-
gosomal membranes (Figures 2j and k). To demonstrate that
the changes in LC3-II were due to increased autophagic flux,
we utilized the GFP–LC3 cleavage assay15 in HEY cells. We
observed that FAC increased GFP cleavage, (Figure 2l)
suggesting that FAC increases autophagic flux.
To assess whether knockdown of essential autophagy
markers alters FAC-induced LC3-II formation, we utilized
siRNA targeting ATG5, ATG7, beclin-1, and hVps34. Knock-
down of these markers was very effective (495% reduction in
protein expression) in contrast to long-term short hairpin RNA
(shRNA) ATG5 knockdown (Supplementary Figure 5a).
Although reduction of LC3-II levels was marked with ATG5
and ATG7 knockdown in T80 cells, there was no effect with
beclin-1 or hVps34 (Figures 3a and b). Cotreatment with
T80 HEY TOV21G
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3-methyladenine (3-MA, inhibitor of hVps34 kinase activity)
with FAC did not alter LC3-II levels (Figure 3c). These results
indicate that the FAC-induced LC3-II increase is ATG5/ATG7-
dependent and beclin-1/hVps34-independent. To assess
whether knockdown of ATG5/ATG7 expression could hinder
the FAC-induced cell death response (Figure 3d), we
assessed cellular viability following ATG5 and ATG7 siRNA
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Ras-independent manner, which contributes only a modest
effect to FAC-induced cell survival implicating other mechan-
isms in modulating FAC-induced cell death response.
FAC alters lysosome abundance in a Ras-independent
manner. TEM analyses (Figure 4a) document increased
numbers of lysosomes following 250 mM FAC treatment
(24 h). The lysosomes could likely correspond to autopha-
golysosomes engaged in the degradation of iron-containing
material. Higher magnification photographs of lysosomes
(Figure 4b) demonstrate the presence of iron particles
(1–3nm), validated by the acquisition of TEM images of iron
in liquid culture media (Supplementary Figure 6). We validated
the presence of altered lysosome numbers via immunofluor-
escence (Figure 4c) and flow cytometry (Figure 4d). This
demonstrates a dramatic increase in lysosome abundance in
response to FAC in both T80 and T80þH-Ras cells. Although
there was a small increase in lysosome numbers in TOV21G
cells, the FAC-induced changes in HEY was variable (no
statistically significant change). Assessment of intracellular
iron was performed using calcein AM, which correlated closely
to that of lysosomes. Collectively, these results implicate a
Ras-independent mechanism in FAC-induced increase of
lysosome numbers. As Hsp70 elicits protection against
lysosomal membrane permeabillization upon cellular treat-
ment with various agents,16 we assessed whether the
reduction of Hsp70 expression via siRNA could modulate
lysosome numbers in T80 cells. However, this led to only a
subtle reduction in FAC-mediated increase in lysosome
abundance, (Figure 4e) suggesting that Hsp70 does not have
a major role in mediating FAC-induced changes in lysosome
abundance in T80 cells.
FAC activates the MAPK pathway to modulate autophagy,
lysosome abundance, and cell death response. Treatment
of T80 cells overexpressing H-Ras or K-Ras with 250mM FAC
demonstrates only a modest increase in the levels of LC3-II in
comparison with parental T80 cells (Figures 5a and b). The
induction of p-AKT and p-ERK appeared to be only subtly
more sustained in the Ras-overexpressing cell lines in
response to FAC, (Figures 5a and c) implicating a Ras-
independent mechanism in the activation of the PI3K/MAPK
signaling cascades. We investigated whether the PI3K/AKT
and MAPK signaling cascades could mediate the observed
changes in LC3-II expression by using the PI3K inhibitor,
LY294002, and the MAPK inhibitor, U0126, in combination
with FAC in parental T80 cells. Decreased LC3-II levels were
noted following inhibition of the MAPK pathway with U0126
(Figure 5d). In contrast, there was little to no effect with the
PI3K/AKT inhibitor in cells cotreated with FAC in contrast to
cells treated with FAC alone. This suggests that activation of
the MAPK signaling pathway lies upstream of changes in LC3-
II expression. This was validated by EGFP–LC3 immuno-
fluorescence (Figures 5e and f). FAC also dramatically
activated the MAPK and PI3K pathways in HEY cells
(Figure 5g). Inhibition of the MAPK pathway with U0126
altered LC3-II levels in HEY similar to T80 (Figure 5g, right
panel). Interestingly, we noted that FAC in combination with
U0126 led to a marked increase in lysosome numbers
compared with either FAC or U0126 alone (together with
increased calcein AM localization to lysosomes) (Figures 5h
and i), in contrast to T80, which did not elicit marked changes
in lysosome numbers upon cotreatment with U0126
(Supplementary Figure 7). These data implicate the MAPK
signaling pathway (independent of Ras, based on data
obtained in the T80 cells) in modulating LC3-II levels and
lysosome abundance in HEY cells.
Remarkably, U0126 was able to reverse the cell death
effect of FAC in the Ras-overexpressing/mutated cell lines
(T80þH-Ras, HEY, and TOV21G but not T80 or TOV112D
cells) as assessed in cell viability assays (Figure 5j) and LDH
cytotoxicity assays in HEY cells (Figure 5k). These results
suggest that the MAPK signaling pathway is essential in
modulating cell survival in response to FAC in a Ras-
dependent manner.
Involvement of Ras in FAC-induced HO-1 induction and
modulation of cell survival. As HO-1 is the rate limiting
enzyme that breaks down heme to free iron, we assessed
whether HO-1 expression was altered with FAC. When iron
was added concurrently upon cell seeding, we observed
elevated HO-1 mRNA and protein relative to untreated T80
cells. Further, in T80 cells overexpressing H-Ras, HO-1
induction (mRNA and protein) was significantly greater 48 h
post-FAC treatment compared with T80 parental cells
(Figures 6a and b). A positive control of arsenic trioxide-
treated T80 cells was used to positively identify HO-1 by real-
time PCR and western analyses (Figure 6c). As NRF2, a
regulator of antioxidant activity, can induce HO-1 expres-
sion,17 we next determined whether HO-1 induction via FAC
occurred in an NRF2-dependent manner via knockdown of
NRF2 in FAC-treated T80 cells. Using real-time PCR, we
observed that NRF2 siRNA (knockdown 480% at mRNA
and protein level) did not alter FAC-induced activation of
HO-1 (Figure 6c). This suggests that the mechanism of
HO-1 induction mediated by FAC is dependent on Ras and
independent of NRF2.
To understand the functional role elicited by HO-1
induction, we generated retroviral stable cell lines over-
expressing HO-1 in T80 cells (Figures 6d and e). Although
adhesion assays did not show significant changes in
cell attachment or in PXDN (marker of cell adhesion)
Figure 4 FAC increases lysosome abundance in a Ras-independent manner in T80 cells. (a) T80 cells were treated with 250 mM FAC from 6 to 24 h followed by TEM
analyses. Images were captured at  3530 and  8730. Blue arrows identify lysosomes. (b) Additional TEM images are shown of T80 cells treated for 24 h, identifying iron
particles within the lysosome (yellow arrows). (c) T80, T80þH-Ras, and HEY cells were seeded onto glass coverslips and exposed to a bolus dose of calcein AM followed by
250mM FAC treatment for 24 h. During the last 1 h of treatment, cells were labeled with Lysotracker red. Cells were imaged using an inverted fluorescent microscope. Results
are representative of two independent experiments. (d) T80, T80þH-Ras, TOV21G, and HEY cells were treated with 250mM FAC for 24 h. During the last 1 h of treatment,
cells were labeled with Lysotracker green. Cells were harvested and analyzed by flow cytometry. Data are expressed as the percentage of Lysotracker green-positive cells.
Results are representative of two independent experiments. * refers to Po0.05. (e) T80 cells were treated with non-targeting control or Hsp70 siRNA followed by treatment
with 250mM FAC with Lysotracker green, and analyzed by flow (left panel). Protein lysates were also collected and analyzed by western blotting with the indicated antibodies
(right panel). Results are representative of two independent experiments
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upon HO-1 overexpression in T80 cells (results not shown),
growth assays implicated HO-1 in inhibition of cell survival
(Figure 6f).
Imbalance of intracellular iron levels mediates cell death
responses. Maintaining appropriate cellular iron balance
(cellular elimination and absorption18) is essential to
prevent toxicity due to its excessive accumulation. To
determine whether disruption of intracellular iron levels leads
to altered cell survival, we utilized DFO (a membrane
permeable iron chelator) to inhibit the activity of iron. We
found that DFO reversed FAC-induced increase in LC3-II at
18 h and early activation of p-AKT (1 h) (Figure 7a). The
cellular morphology reverted to normal when DFO was
utilized at a 1 : 1 ratio with FAC. Although we noted a marked
reduction in cleaved poly ADP-ribose polymerase (PARP)
when DFO (Figure 7a) was added concurrently with FAC,
there was only a subtle change in overall cell survival in T80
cells (Supplementary Figure 8). We validated these LC3-II
changes by EGFP–LC3 immunofluorescence (Figures 7b
and c). The data shows that DFO reverses punctae formation
induced by FAC. Like the T80 results presented in Figure 7a,
changes in LC3-II, p-AKT, and p-ERK were similarly
observed in HEY in response to DFO in the absence/
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presence of FAC (Figure 7d). Strikingly, DFO markedly
affected cell survival in multiple ovarian cancer cell lines
(Figures 7e–g). Collectively, these results suggest that
disruption of intracellular iron is detrimental to cell survival;
further, the addition of equimolar equivalents of FAC to DFO
can partially oppose the cell death-inducing effect of the iron
chelating agent.
Discussion
Iron is an essential element needed to modulate multiple
cellular functions to sustain tumor growth. This important
nutrient is elevated in cystic fluid of endometriosis-associated
ovarian cancers, a potential cause of clear cell cancer
development via persistent oxidative stress.3,4 Although
reports indicate that cancer cell lines respond to iron
with increased proliferative indices, we demonstrate that iron
is detrimental to the survival of ovarian cancer cells
associated with Ras mutations (Figure 8). Although the
frequency of Ras mutations in ovarian cancers is variable
owing to the heterogeneity of this disease, we propose
that cellular sensitivity towards iron may be a novel targeting
strategy. Maintaining appropriate cellular iron levels is
critical; indeed, the use of DFO, an iron chelating agent,
induces apoptotic cell death in ovarian cells similar to that
reported.19
The nature of the reduced survival induced by FAC in the
sensitive cell lines appeared diverse. Although FAC induced
necrosis in HEY, the nature of the reduced survival in
TOV21G needs further investigation. In this respect, it is
interesting that ferroptosis (a novel regulated cell death
mechanism induced by erastin that targets iron-regulatory
protein 2, which controls the translation of mRNAs involved in
iron homeostasis)6 selectively kills cells expressing oncogenic
mutants of Ras. Ferroptosis is dependent on iron, ROS,
NADPH-dependent oxidases, lipid peroxidation, and pre-
sence of electron-dense mitochondria, whereas it is indepen-
dent of caspase activation.6 Although our results with
ferrostatin-1, an inhibitor of ferroptosis, indicate a modest
effect on LC3-II levels and EGFP–LC3 punctae formation
(Supplementary Figure 9a-9c), it remains to be determined
whether this pathway modulates FAC-induced cell death
response in ovarian cells.
We demonstrate that the MAPK signaling pathway is
essential in modulating FAC-induced cell survival response
in Ras-overexpressing/mutated cell lines. HEY and TOV21G
have reduced p66 Shc levels (and activating Ras mutations
and high basal LC3-II levels (Supplementary Figure 4)) in
contrast to TOV112D, T80, and IE cells (Supplementary
Figure 3). Upstream of MAPK, p66 Shc opposes the activity of
Ras to control proliferation and anchorage-dependent respon-
siveness.20 Although Shc siRNA did not alter LC3-II levels or
cell survival in T80 cells (results not shown), Ras hyperactiva-
tion via mutation or overexpression in T80 cells leads to
increased cell death similar to that observed in tetracycline-
inducible H-RasV12 HOSE cells.21
In addition, we report altered autophagic flux and lysosome
numbers, occurring in a Ras-independent manner, in response
to FAC. The marked increase in lysosome abundance in T80
and T80þH-Ras cells, but not in HEY/TOV21G cells could
implicate an aberration in the lysosomal membranes of HEY/
TOV21G cells. HEY are particularly vulnerable to FAC (necrotic
response). Entry of ferritin into lysosomes may occur in an
autophagy-dependent manner leading to the accumulation of
redox-active iron within lysosomes.22 If lysosomes become
destabilized, membrane damage and release of redox-active
iron into the cytosol may ensue, leading to cellular damage
via Fenton-type reactions, and thus cell death. However,
knockdown of Hsp70 in T80 did not significantly reduce
lysosome numbers without any effect on survival potential in
response to iron. As there was only a modest reversal effect on
FAC-induced cell death in HEY when ATG5/ATG7 expression
was reduced, other mechanisms could compensate for the
reduction in macroautophagy including chaperone-mediated
autophagy or microautophagy for the movement of iron into the
lysosomal compartment.
We also identified that HO-1 was elevated with FAC in T80
cells with H-Ras overexpression relative to parental T80
and that HO-1 overexpression in T80 reduces growth
potential. These results support findings in the lung cancer
A549 and kidney LLC-PK1 cells.23,24 We further demon-
strate that transcriptional regulation of HO-1 expression
Figure 5 FAC modulates autophagy, lysosome abundance, and cell survival in a MAPK-dependent manner. (a) T80, T80þH-Ras, and T80þK-Ras were treated with
250mM FAC for the indicated time points (1–18 h). Cell lysates were collected and analyzed by western blotting for the proteins indicated. Results are representative of four
independent experiments. (b) Cell lysates collected from T80, T80þH-Ras, and T80þK-Ras followed by western analyses for H-Ras and K-Ras expression. (c) T80 and
T80þH-Ras cells were treated with 250mM FAC for the indicated time points (5 min–3 h). Cell lysates were collected and analyzed by western blotting for the proteins
indicated. Results are representative of four independent experiments. (d) Top panel, T80 cells were treated with (1) 10 mM U0126, (2) 250mM FAC, or (3) 10mM U0126 and
250mM FAC for 1–18 h. Cell lysates were harvested and analyzed for the proteins indicated. Results are representative of three independent experiments. Bottom panel, T80
cells were treated with (1) 75 mM LY294002, (2) 250mM FAC, or (3) 75mM LY294002 and 250mM FAC for 1–18 h. Cell lysates were harvested and analyzed for the proteins
indicated. Results are representative of three independent experiments. (e) T80 cells were transfected with EGFP–LC3 and treated with (1) 10mM U0126, (2) 75mM
LY294002, (3) 250mM FAC, (4) 10mM U0126 with 250mM FAC, or (5) 75mM LY294002 with 250mM FAC for 18 h. EGFP–LC3 fluorescence was captured using an inverted
fluorescence microscope at  40 magnification. Representative images of experiments conducted in duplicate are shown. (f) results from (e) are shown as the number of cells
with punctae quantified by counting 200 cells with420 punctae. (g) HEY cells were treated with 250mM FAC (left panel) or in combination with 10 mM U0126 (right panel) for
the indicate times followed by western analyses. Results are representative of two independent experiments. (h) HEY cells were seeded onto glass coverslips and exposed to
a bolus dose of calcein AM followed by 250 mM FAC treatment in the absence or presence of 10 mM U0126 for 24 h. During the last 1 h of treatment, cells were labeled with
Lysotracker red. Cells were imaged using an inverted fluorescent microscope. Results are representative of two independent experiments. (i) HEY cells were treated with
250mM FAC in the absence or presence of 10 mM U0126 for 24 h. During the last 1 h of treatment, cells were labeled with Lysotracker green. Cells were harvested and
analyzed by flow cytometry. Data are expressed as the percentage of Lysotracker green-positive cells. Results are representative of two independent experiments. (j) T80,
T80þH-Ras, HEY, TOV112D, and TOV21G cells were treated in combination with 10 mMU0126 and 250mM FAC compared with either 10mMU0126 or 250mM FAC alone.
Cell growth was assessed and results shown are representative of two independent experiments. (k) HEY cells were treated with 250mM FAC in the absence or presence of
10mM U0126 for 72 h followed by measurement of LDH activity. Results are representative of two independent experiments. * refers to Po0.05
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occurs via an NRF2-independent manner similar to human
keratinocytes.25 Although HO-1 overexpression in BeWo
choriocarcinoma cells increased tumor cell adhesion and
expression of PXDN,26 we did not observe marked changes
in PXDN or adhesion function with HO-1 overexpression in
T80 cells.
The results presented herein can be classified into four
major categories: (1) Ras-dependent, (2) Ras-independent,
(3) MAPK-dependent, and (4) Ras- and MAPK-dependent
(Supplementary Figure 10). In support of the discordance in
our results between Ras and the MAPK signaling cascade,
there are reports of Ras-independent activation of MAP
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Figure 6 FACmodulates HO-1 expression and survival in T80 cells. (a) T80 and T80þH-Ras cells were treated with 250mM FAC concurrently upon seeding. Cell lysates
were harvested 72 h post-seeding and analyzed by western blotting for the proteins indicated. (b) T80 and T80þH-Ras cells were treated with 250mM FAC concurrently with
seeding. RNA was harvested 72 h post-seeding and analyzed by real-time PCR for HO-1 expression. (c) T80 cells were transfected with NRF2 siRNA followed by treatment
with 250mM FAC performed concurrently upon seeding. RNA was isolated and quantified for NRF2 and HO-1 RNA transcripts (top panels). In the lower panels, T80 cells were
treated with 10mM As2O3, RNA isolated following 72 h treatment, and analyzed by real-time PCR for HO-1. Western analysis of NRF2 knockdown is shown in the bottom right
panel. Results are representative of four independent experiments. (d) HO-1 retroviral stable cell lines were generated in T80 cells. Cell lysates were harvested and analyzed
for HO-1 expression with GAPDH as a loading control. (e) RNA was isolated from T80 retroviral stable cells overexpressing HO-1. Real-time PCR was performed to quantify
HO-1 mRNA levels. (f) Both HO-1 and vector control retroviral stable T80 cells were assessed for relative growth. Results shown are representative of four independent
experiments. * refers to Po0.05
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kinase: (1) calcium-induced differentiation of keratinocytes
mediated via Ras-independent activation of the Raf/MEK/
ERK pathway,27 (2) Ras-independent activation of the MAPK
signaling pathway during cardiomyocyte stretch response,28
and (3) leukotriene D4 Ras-independent/PKCe-dependent
activation of MAPK in intestinal epithelial cells.29 Both HEY
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and TOV21G are reported to have Ras mutations; however,
these cell lines (and TOV112D) are likely to contain mutations
in additional oncogenes (including PI3K) that may have a role
in FAC-mediated cellular responses. Thus, although our
studies focus on Ras/MAPK signaling, other cascades may
likely contribute to FAC-induced responses. This is currently
being investigated using a proteomic profiling (reverse phase
protein array) approach (Bauckman et al., unpublished
observations).
Materials and Methods
Cell lines. HEY ovarian carcinoma cells and T80 immortalized (LTAg/hTERT)
normal ovarian surface epithelial cells (kindly provided by Dr. Gordon Mills, MD
Anderson Cancer Center, Houston, TX, USA) were maintained in RPMI 1640
supplemented in 8% FBS and penicillin/streptomycin. T80 cells overexpressing
H-Ras or K-Ras (kindly provided by Dr. Jinsong Liu (MD Anderson Cancer
Center), and Dr. Gordon Mills (MD Anderson Cancer Center)) were maintained in
RPMI 1640 in 8% FBS and penicillin/streptomycin. TOV112D endometrioid
ovarian carcinoma cells (obtained from ATCC, Manassas, VA, USA) and TOV21G
CCC cells (kindly provided by Dr. Jonathan Lancaster, Moffitt Cancer Center,
Tampa, FL, USA) were maintained in MCDB131:Medium 199 (1 : 1 ratio)
supplemented with 8% FBS and penicillin/streptomycin. HES normal endometrial
epithelial cell line (kindly provided by Dr. Douglas Kniss, Ohio State University
Medical Center, Columbus, OH, USA) was maintained in DMEM (high glucose)
supplemented in 8% FBS and penicillin/streptomycin. The HES cell line, although
considered a normal endometrial line, has recently been identified to express
markers present in HeLa cells.10 All cell lines were tested to be mycoplasma
negative before use in the studies reported herein.
Immortalization of primary endometriotic cells. Primary
endometriotic cells derived from endometriotic lesions were obtained from Dr.
Idhaliz Flores (PSMHS, Ponce, Puerto Rico) and grown in MCDB131:Medium
199 (1 : 1 ratio) supplemented with 8% FBS, penicillin/streptomycin, and
insulin/transferrin/selenium (ITS) (Bello et al., unpublished data). To generate
SV40 LTAg immortalized endometriotic (IE) cell lines, we obtained the LTAg-
pBABE-puro vector (Addgene, Cambridge, MA, USA). We generated retroviral
particles using HEK293T packaging cells transfected with this vector in
combination with pCGP and pVSVG vectors. Forty-eight and 72 h post-
transfection, retroviral particles were collected and used to infect the primary
cells. Infected primary cells were then treated with puromycin-containing media
(2.5mg/ml) to select for resistant colonies. These colonies developed B1 month
following puromycin selection. Six clones were isolated, expanded, and validated.
The IE were maintained in MCDB131:Medium 199 (1 : 1 ratio) supplemented with
8% FBS and penicillin/streptomycin. The characteristics of the primary and
immortalized IE cells were validated by western blotting for LTAg and by
immunocytochemical staining for cytokeratin 18 (positive) and for vimentin
(negative) (Bello et al., unpublished data).
Isolation of genomic DNA from IE cells. IE cells were grown to
confluence (P¼ 3 following immortalization) in a T25 flask from which genomic
DNA was isolated. The genomic DNA DNeasy Blood and Tissue kit from Qiagen
(Valencia, CA, USA) was utilized.
Detection of mutations in PIK3CA and K-Ras in IE cells by
genomic PCR-sequencing. PCR conditions were as follows: 94 1C for
2min, 40 cycles of 94 1C for 1min, 45 1C for 1 min, 68 1C for 1min, and
final extension at 72 1C for 10min. PCR products were run on a 1.5% agarose gel
and appropriate bands were gel purified (Qiagen) and sequenced (Moffitt Cancer
Center, Molecular Biology Core).
PIK3CA exon 20 forward: 50-TTGATGACATTGCATACATTCG-30
PIK3CA exon 20 reverse: 50-AATTGTGTGGAAGATCCAATCC-30
PIK3CA exon 9 forward: 50-GAATCCAGAGGGGAAAAA-30
PIK3CA exon 9 reverse: 50-CCATTTTAGCACTTACCTGTG-30
K-Ras forward primer: 50-GCCTGCTGAAAATGACTGAA-30
K-Ras reverse primer: 50-GTTGGATCATATTCGTCCACA-30
Cloning of HO-1. RNA from T80 cells was isolated using the RNeasy kit
(Qiagen) and quantified using Nanodrop. PCR was performed using the following
forward and reverse primers:
Forward primer: 50-GGAATTCACCATGGAGCGTCCGCAAC-30
Reverse primer: 50-GGAATTCTCACATGGCATAAAGC-30
PCR conditions were as follows: 48 1C for 30min, 94 1C for 2min, 40 cycles of
denaturation at 94 1C for 1min, annealing at 60 1C for 1min, extension at 68 1C for
5min, and final extension at 72 1C for 15min. The PCR product was cloned into the
pTOPO vector (Invitrogen, Carlsbad, CA, USA), positive clones selected by restriction
enzyme digestion with EcoRI, and sequenced using M13 Forward and M13 Reverse
primers (Moffitt Cancer Center, Molecular Biology Core). Once a positive clone was
identified, the insert was digested overnight with EcoRI together with empty pBABE-
puro plasmid. Insert was gel purified whereas the vector was dephosphorylated using
Antarctic Acid Phosphatase (NEB, Ipswich, MA, USA). Insert was then ligated to the
dephosphorylated vector using T4 Quick DNA Ligase (NEB). Positive clones were
selected by restriction enzyme digestion and sequencing. High quality plasmid was
obtained by Maxi Large Plasmid Preparation (Qiagen).
Generation of HO-1 overexpression and ATG5 shRNA retroviral
stable cell lines. HO-1 retroviral stable cell lines were generated in T80 cells.
HEK293T packaging cells were utilized to generate replication defective viruses.
pSUPER control and ATG5 shRNA (two distinct shRNAi targeting ATG5: H2
and H7) retroviral plasmid constructs were generously provided by Xiao-Feng Zhu
(State Key Laboratory of Oncology in South China, Guangzhou, China). ATG5
shRNA was utilized to attempt knockdown of endogenous ATG5 in HEY, T80,
TOV112D, and TOV21G cell lines. Using HEK293T packaging cells, ATG5 shRNA
was transfected together with pCGP and pVSVG vectors using Fugene HD (Roche,
Indianapolis, IN, USA). Forty-eight and 72 h post-transfection, retroviral particles
were collected and used to infect the ovarian cells. Infected cells were then treated
with puromycin-containing media (2mg/ml for HEY, 1mg/ml for T80, 2mg/ml for
TOV112D, and 2mg/ml for TOV21G) to obtain retroviral parental cell populations.
Positive knockdown of ATG5 protein expression was validated by western analyses.
HO-1 overexpression was validated by both real-time PCR and western analyses.
Cellular treatments with inhibitors. Chloroquine (Fisher Scientific,
Pittsburgh, PA, USA)(12.5 or 25mM) was dissolved in tissue culture-grade water.
Ferric ammonium citrate (Fisher Scientific) was utilized between 5mM to 10mM
and dissolved in tissue culture-grade water. Deferoxamine mesylate (Sigma-
Aldrich, St. Louis, MO, USA) was used between 1 nM to 250mM, and dissolved in
tissue culture-grade water. Ferrostatin (no. 9065366, C15H22N2O2, ChemBridge,
San Diego, CA, USA) was used at 100 mM and dissolved in dimethylsulfoxide
Figure 7 FAC antagonizes the reduction in cell survival induced by DFO, an iron chelating agent, in ovarian cancer cells. (a) T80 cells were treated with (1) 100mM DFO,
(2) 250mMDFO, (3) 250mM FAC, (4) 250mM FAC with 100mMDFO, or (5) 250mM FAC with 250mMDFO for 1 or 18 h. Cell lysates were harvested and analyzed by western
blotting for the indicated proteins. Results are representative of two independent experiments. (b) T80 cells were transfected with EGFP–LC3 and treated with (1) 250mM
DFO, (2) 250mM FAC, or (3) 250mM DFO with 250mM FAC for 18 h. EGFP–LC3 fluorescence was captured using an inverted fluorescence microscope at  40
magnification. Representative images of experiments conducted in duplicate are shown. (c) Results from (b) are shown as the number of cells with punctae quantified by
counting 200 cells with420 punctae. (d) HEY cells were treated with (1) 100mM DFO, (2) 250mM DFO, (3) 250mM FAC, (4) 250 mM FAC with 100mM DFO, or (5) 250mM
FAC with 250mM DFO for 1 or 18 h. Cell lysates were harvested and analyzed by western blotting for the indicated proteins. Results are representative of two independent
experiments. (e) HEY, TOV112D, and TOV21G cells were treated with (1) 250mM DFO alone, (2) 250mM FAC alone, or (3) 250mM DFO and 250mM FAC. Cell growth was
assessed. Results are representative of two independent experiments. (f) T80, HEY, TOV21G, and TOV112D cells were treated with increasing doses of DFO (1 nM–25mM).
Cellular survival was assessed and results are shown as relative growth. Results are representative of two independent experiments. (g) HEY and TOV21G cells were treated
in combination with 1–25 mM DFO and 1–25mM FAC compared with either 1–25 mM DFO or 1–25 mM FAC alone. Cell growth was assessed. Results shown are
representative of two independent experiments. * refers to Po0.05
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(DMSO). U0126 and LY294002 were obtained from Cell Signaling Technology
(Danvers, MA, USA) and used at doses of 10 mM and 75mM, respectively
(dissolved in DMSO).
Cellular treatments with siRNA. T80 cells were seeded at 325 000 cells
per well in a 6-well plate. Following overnight adherence, cells were trans-
fected with siRNA targeting NRF2 (L-003755-00), ATG6/beclin-1 (L-010552-22),
ATG7 (L-020112-00), hVps34 (L-005250-00), H-Ras (L-004142-00), K-Ras
(L-005069-00), Hsp70 (L-021084-01), or non-targeting ON-TargetPLUS control
(D-001810-10) with Dharmafect I (ThermoScientific, Pittsburgh, PA, USA) using
methods previously described. ShcA p66 siRNA was custom designed based on a
published sequence towards its CH2 domain.30 The sense sequence is
50-GAAUGAGUCUCUGUCAUCGUU-30 and antisense sequence is 50-CGAUGAC
AGAGACUCAUUCUU-30. The siRNA transfection method was followed according
to our previously published studies.31 For NRF2 siRNA studies, cells were
trypsinized and reseeded in media containing FAC (250mM) and cultured for 48 h
before RNA and protein harvest for quantitative polymerase chain reaction
(qPCR) and western analyses, respectively.
Protein isolation, SDS-PAGE, and western blot analyses. Protein
isolation and western blot analyses were performed according to previously
published methods.31 Primary antibodies were used at the following dilutions.
LC3B rabbit polyclonal (no. 2775, 1 : 1000), p-AKT (Ser473) rabbit polyclonal
(no. 4060, 1 : 1000), p-ERK 1/2 rabbit polyclonal (no. 9101, 1 : 1000), total AKT
rabbit polyclonal (no. 4685, 1 : 1000), total MAPK rabbit polyclonal (no. 4695,
1 : 1000), ATG5 rabbit polyclonal (no. 2630, 1 : 1000), HO-1 rabbit polyclonal
(no. 5061, 1 : 100), GAPDH rabbit polyclonal (no. 2118, 1 : 4000), FTH1 (ferritin)
rabbit polyclonal (no. 3998, 1 : 1000), NRF2 rabbit monoclonal (no. 8882, 1 : 1000),
total Ras rabbit monoclonal (no. 3339, 1 : 1000), PARP rabbit polyclonal (no. 9542,
1 : 1000), LAMP-1 rabbit monoclonal (no. 9091, 1 : 1000), Beclin-1 rabbit
polyclonal (no. 3738, 1 : 1000), and hVps34 rabbit polyclonal (no. 3358,
1 : 1000) antibodies were obtained from Cell Signaling Technology. Shc rabbit
polyclonal (no. 06-203, 1 : 1000) antibody was obtained from Millipore (Billerica, MA,
USA). CD71 mouse monoclonal antibody (2B6, transferrin receptor, sc-51829,
1 : 1000) and K-Ras mouse monoclonal (F234, sc-30, 1 : 100) antibodies were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). ATG7 rabbit
polyclonal (1 : 1000) antibody was obtained from MBL International (Woburn, MA,
USA). p62 mouse monoclonal (1 : 1000) antibody was obtained from BD Biosciences
(San Jose, CA, USA). Hsp70 mouse monoclonal (SMC-100, 1 : 1000) antibody was
obtained from StressMarq (Victoria, BC, Canada).
RNA isolation and quantitative polymerase chain reaction. Total
RNA was isolated using the RNeasy Mini Kit (Qiagen). HO-1 (HMOX,
Hs01110250_m1) or NRF2 (NFE2L2, Hs00975961_g1) and One-step master
Figure 8 Proposed model of iron-induced effects in gynecological cells. (a) FAC treatment leads to the activation of MAPK through which it mediates effects on
LC3-II/autophagy in an ATG5/7-dependent, beclin-1/hVps34-independent, and Ras-independent manner. In addition, FAC modulates lysosome abundance in a
Ras-independent pathway. Further, reduction of the cell death response was altered by U0126, an inhibitor of MAPK. (b) Ras-dependent changes in HO-1 were observed in
T80 cells treated with FAC. HO-1 overexpression leads to decreased cell survival in T80 cells. (c) In HEY cells, DFO (an iron chelating agent) leads to induction of apoptosis,
whereas FAC induces a necrotic cell death response. Increased cell survival was observed upon cotreatment of FAC and DFO in HEY, TOV21G, and TOV112D cells
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mix (Applied Biosystems, Foster City, CA, USA) was used in qPCR using
previously described PCR conditions.31 Results were analyzed by the comparative
method using untreated cells as the reference sample and b-actin for normali-
zation. RNA-fold changes were calculated using the following formula: 2DDCT.
Direct and indirect immunofluorescence. Cells were seeded onto
coverslips and allowed to adhere following overnight incubation. Cells were then
transfected with EGFP–LC3 (Addgene, Cambridge, MA, USA) and prepared for
direct immunofluorescence according to previously published methods.31 The cells
were viewed under a Zeiss inverted fluorescence microscope (Carl Zeiss
Incorporated, Thornwood, NY, USA) at the Microscopy Core at the Moffitt Cancer
Center. Quantification of EGFP–LC3 expressing cells was performed by
counting the number of cells expressing a punctate pattern in a total of 200
EGFP–LC3-positive cells (at least 20 punctae).
Transmission electron microscopy. Matched cultures of control and
experimental cells grown to confluence, exposed to FAC at 0, 6, 18, and 24 h,
were submitted for TEM. The samples were fixed in 0.1 M phosphate buffered
2.5% glutaraldehyde overnight, post-fixed for 1 h in buffered 1% osmium tetroxide,
dehydrated in a graded series of acetone, and embedded in LX 112 epoxy resin.
Following polymerization, thin sections obtained from blocks of the samples were
stained with 8% aqueous uranyl acetate and Reynold’s lead citrate, then observed
and photographed on an FEI Morgagni 268D (FEI Company, Inc, Hillsboro, OR,
USA) TEM at various magnifications.
Cell cycle analysis. Cell cycle analysis was performed utilizing propidium iodide
with 0.01% Triton X-100 and 2mg of DNAse-free RNAse A followed by analysis by
flow cytometry (College of Medicine, University of South Florida, Tampa, FL, USA).
Intracellular ATP measurements. For Cell Titer Glo assays, cells were
seeded at 5000 cells/well (IE, HES, and TOV112D, and TOV21G) or 2500 cells/
well (T80, HEY, and H460) in white opaque 96-well plates followed by cellular
treatment with 250mM FAC. ATP levels were measured according to
manufacturer’s instructions (Promega, Madison, WI, USA).
Wound healing assays. This assay was performed using the CytoSelect
24-well plate (Cell Biolabs, San Diego, CA, USA). Briefly, cells were seeded at
250 000 (T80), 500 000 (TOV112D, TOV21G, and T80þH-Ras), 400 000
(T80þK-Ras), and 200 000 (HEY) cells. Following cellular adherence and
scratching of the monolayer, the cells were then treated with 250mM FAC for 18 h
followed by cell staining and image analyses.
Growth assays. For colony formation assays, cells were seeded at 500 cells/
well in a 6-well plate. Following cell adherence, cells were treated in the presence
or absence of 25mM CQ. Plates were then stained with crystal violet following
an B2 week period.
For standard growth assays, cells were seeded at 5000 cells/well (IE, HES,
TOV112D, and TOV21G) or 2500 cells/well (T80 and HEY) in 96-well plates.
Following cell adherence, cells were treated appropriately. Plates were stained at
appropriate selected times with crystal violet and quantified at 570 nm upon
dissolution in Sorenson’s buffer.
Calcein AM. This protocol was followed according to published methods with
modifications.32 Briefly, before cellular treatment with FAC, the media was
removed and 1ml of a 0.15 mM Calcein AM (Invitrogen, Grand Island, NY, USA)
prepared in 1 mg/ml BSA, 20mM Hepes, and phosphate-buffered saline (PBS)
was added to cells grown in six-well plates. Cells were then treated for 15min at
37 1C. Cells were washed and then treated with FAC for the desired time period.
BD LSRII set at a 488 nm excitation and 530/30 emission wavelength was utilized
with BD FacsDiva 6.1.3 software for recording and analysis.
Quantification of lysosomes. For immunofluorescence staining, cells
were seeded onto glass coverslips, allowed to adhere, and then treated with
250mM FAC for 24 h. Lysotracker red (Invitrogen) was added (75 nM) 1 h before
completion of FAC treatment. For flow analysis, cells were plated into 6-well
plates, allowed to adhere, followed by FAC treatment. At 1 h before completion,
media was removed and replaced with warm media containing a 75 nM of
Lysotracker green (Invitrogen). Cells were then trypsinized and resuspended in
PBS followed by flow cytometry. BD LSRII with 488 nm excitation and 530/30
emission were used together with software for recording and analysis (BD
FacsDiva 6.1.3).
LDH assays. Cells were plated in 96-well plates at a cell density of 2500 in 1%
FBS-containing media. The day following seeding, cells were overlayed with media
containing 250mM FAC in 1% FBS-containing media. After 72 h treatment, plates
were spun down, followed by removal of 100ml of culture media from each well,
which was transferred to a new 96-well plate, to which 100ml of LDH reaction
mixture (Fisher Scientific) was added. Samples were then incubated for 30min
followed by acquisition of LDH measurements at 490 nm. Relative cytotoxicity
measurements were determined by subtracting the background (1% FBS media
only) from each experimental sample.
Annexin V/PI apoptosis assays. Annexin V/PI staining (Calbiochem,
San Diego, CA, USA) was performed according to our previous publication.31
The samples were analyzed by flow cytometry at the University of South Florida
Health—College of Medicine FACS Core Facility.
Senescence assays. Measurement of b-galactosidase senescence activity
was performed according to manufacturer’s protocol (Cell Signaling Technology).
Statistical analyses. Experimental replicates were conducted as indicated
in each figure legend presented. Error bars displayed on the bar graphs
represent S.D. P-values were calculated using Prism (standard Student’s t-test).
NS refers to not significant P-values (P40.05); * refers to Po0.05; ** refers to
Po0.01; *** refers to Po0.0001.
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